On June 26, Tianjin Pharmaceutical Group Co., Ltd. issued an announcement stating that its subsidiary, Tianjin Pharmaceutical Peace Co., Ltd., received the "Approval Notice for Supplementary Application for Drug" for low-calcium peritoneal dialysis solution issued by the National Medical Products Administration, approving the product to pass the consistency evaluation of generic drug quality and efficacy.

It is understood that low-calcium peritoneal dialysis solution is suitable for patients with acute and chronic renal failure who require continuous ambulatory peritoneal dialysis treatment due to ineffective non-dialysis therapies. This successful evaluation further enhances the competitive advantage of Tianjin Pharmaceutical Group's pharmaceutical preparations in the domestic market, facilitating market expansion and continuously increasing the market share of its pharmaceutical preparations in China.

Articles: Board Office of Tianjin Pharmaceutical Group Co., Ltd., China Securities Journal (China Securities Network)